This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 25/12/2642    most recent 01.ATV.0000192018.90021.c0v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Wanrooij, E. J.A. Articles by Kuiper, J. Search for Related Content PubMed PubMed Citation Articles by van Wanrooij, E. J.A. Articles by Kuiper, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information AIDS Medicines Hazardous Substances DB CHOLESTEROL Related Collections Mechanism of atherosclerosis/growth factors Animal models of human disease Risk Factors Gene expression Growth factors/cytokines Related Article

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:2642.)
© 2005 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

HIV Entry Inhibitor TAK-779 Attenuates Atherogenesis in Low-Density Lipoprotein Receptor–Deficient Mice

Eva J.A. van Wanrooij; Hester Happé; Arnaud D. Hauer; Paula de Vos; Takeshi Imanishi; Hiromi Fujiwara; Theo J.C. van Berkel; Johan Kuiper

From the Division of Biopharmaceutics (E.J.A.v.W., H.H., A.H., P.d.V., T.J.C.v.B., J.K.), Leiden/Amsterdam Center for Drug Research, Gorlaeus Laboratories, Leiden, The Netherlands; and the Department of Bioorganic Chemistry (T.I.), Graduate School of Pharmaceutical Sciences, Osaka University, and the Department of Oncology (H.F.), Osaka University Graduate School of Medicine, Osaka, Japan.

Correspondence to Eva J.A. van Wanrooij, Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Gorlaeus Laboratories, Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands. E-mail e.van.wanrooij{at}chem.leidenuniv.nl

Objective— HIV combination therapy using protease inhibitors is associated with elevated plasma levels of atherogenic lipoproteins and increased risk for atherosclerosis. We investigated whether the HIV entry inhibitor TAK-779 affects lipoprotein levels and atherogenesis in low-density lipoprotein receptor-deficient mice. TAK-779 is an antagonist for the chemokine receptors CCR5 and CXCR3, which are expressed on leukocytes, especially T-helper 1 cells, and these receptors may be involved in recruitment of these cells to atherosclerotic plaques.

Methods and Results— TAK-779 treatment of low-density lipoprotein receptor^–deficient mice did not elevate the levels of atherogenic lipoproteins, whereas it dramatically reduced atherosclerosis in the aortic root and in the carotid arteries. The number of T cells in the plaque was reduced by 95%, concurrently with a 98% reduction in the relative IFN- area. TAK-779-treated animals showed a decreased percentage of CD4⁺ and CD8⁺ T cells in peripheral blood and in mediastinal lymph nodes compared with control-treated animals.

Conclusions— TAK-779 not only suppresses HIV entry via blockade of CCR5 but also attenuates atherosclerotic lesion formation by blocking the influx of T-helper 1 cells into the plaque. TAK-779 treatment may be especially beneficial for young HIV patients as they face lifelong treatment, and this drug impairs atherogenesis.

The HIV entry inhibitor TAK-779, a CCR5/CXCR3 antagonist, reduced atherogenesis by blocking the influx of Th1 cells into the plaque. We conclude that HIV entry inhibitors, because of their antiatherogenic properties, are preferred for treatment of HIV-positive patients.

Key Words: atherosclerosis • chemokines • HIV • T cells • CCR5

Related Article:

Killing Two Birds With One Stone: Targeting Chemokine Receptors in Atherosclerosis and HIV Infection

Christian Weber
Arterioscler. Thromb. Vasc. Biol. 2005 25: 2448-2450. [Full Text] [PDF]

This article has been cited by other articles:

				V. Braunersreuther, S. Steffens, C. Arnaud, G. Pelli, F. Burger, A. Proudfoot, and F. Mach A Novel RANTES Antagonist Prevents Progression of Established Atherosclerotic Lesions in Mice Arterioscler. Thromb. Vasc. Biol., June 1, 2008; 28(6): 1090 - 1096. [Abstract] [Full Text] [PDF]

				E. J.A. van Wanrooij, S. C.A. de Jager, T. van Es, P. de Vos, H. L. Birch, D. A. Owen, R. J. Watson, E. A.L. Biessen, G. A. Chapman, T. J.C. van Berkel, et al. CXCR3 Antagonist NBI-74330 Attenuates Atherosclerotic Plaque Formation in LDL Receptor-Deficient Mice Arterioscler. Thromb. Vasc. Biol., February 1, 2008; 28(2): 251 - 257. [Abstract] [Full Text] [PDF]

				S. I. van Leuven, R. Franssen, J. J. Kastelein, M. Levi, E. S. G. Stroes, and P. P. Tak Systemic inflammation as a risk factor for atherothrombosis Rheumatology, January 1, 2008; 47(1): 3 - 7. [Abstract] [Full Text] [PDF]

				A. D. Hauer, G. H.M. van Puijvelde, N. Peterse, P. de Vos, V. van Weel, E. J.A. van Wanrooij, E. A.L. Biessen, P. H.A. Quax, A. G. Niethammer, R. A. Reisfeld, et al. Vaccination Against VEGFR2 Attenuates Initiation and Progression of Atherosclerosis Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 2050 - 2057. [Abstract] [Full Text] [PDF]

				H. Wu, S. Ghosh, X. D. Perrard, L. Feng, G. E. Garcia, J. L. Perrard, J. F. Sweeney, L. E. Peterson, L. Chan, C. W. Smith, et al. T-Cell Accumulation and Regulated on Activation, Normal T Cell Expressed and Secreted Upregulation in Adipose Tissue in Obesity Circulation, February 27, 2007; 115(8): 1029 - 1038. [Abstract] [Full Text] [PDF]

				V. Braunersreuther, A. Zernecke, C. Arnaud, E. A. Liehn, S. Steffens, E. Shagdarsuren, K. Bidzhekov, F. Burger, G. Pelli, B. Luckow, et al. Ccr5 But Not Ccr1 Deficiency Reduces Development of Diet-Induced Atherosclerosis in Mice Arterioscler. Thromb. Vasc. Biol., February 1, 2007; 27(2): 373 - 379. [Abstract] [Full Text] [PDF]

				C. Weber Killing Two Birds With One Stone: Targeting Chemokine Receptors in Atherosclerosis and HIV Infection Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2448 - 2450. [Full Text] [PDF]